Cancer

Sci-Bytes

Glioblastoma multiforme (GBM) is the most common form of brain tumor in adults, responsible for more than half of all brain tumors. Prognosis is generally very poor, with survival measured in...

Cancer Treatments Have Very Few Toxic Side Effects
Sci-Bytes

Drug development is so much more precise, binding to specific proteins and using antibodies to give exact mechanisms of action, that the debilitating...

Sci-Bytes

“Why me?” is a direct or implied question from many patients diagnosed with cancer, but there is rarely a simple answer. At some point in any discussion with healthcare professionals or during the...

Sci-Bytes

According to a recent analysis of Thomson Reuters Web of Science, the 2012 report “Intratumor heterogeneity and branched evolution revealed by multiregion sequencing,” (M. Gerlinger, et al., New...

Sci-Bytes

Biomedical science has been quick to emulate the open-source model, derived from software development, at least in some spheres. It is hard, however, to imagine an open-source model for drug...

Weekly Byte

Abstract: “We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase...

Weekly Byte

Abstract: “To characterize somatic alterations in colorectal carcinoma, we conducted a genome-scale analysis of 276 samples, analysing exome sequence, DNA copy number, promoter methylation and...

Weekly Byte

Abstract: “BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate...

Weekly Byte

Abstract:“We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase...

Weekly Byte

Abstract: “BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after...

Weekly Byte

Abstract: “BACKGROUND Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and...

Weekly Byte

[Authors' affiliations: 7 institutions worldwide]

Pages